Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

References

• Williams MJ, Johnson K, Trenz HM, et al. Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate. Curr Med Res Opin. 2018;34(1):107–115. doi:10.1080/03007995.2017.1374937
   PubMed Web of Science ®Google Scholar
• Remington G, Rodriguez Y, Logan D, Williamson C, Treadaway K. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care. 2013;15(1):36–45. doi:10.7224/1537-2073.2011-038
   PubMedGoogle Scholar
• Erbay O, Usta Yesilbalkan O, Yuceyar N. Factors affecting the adherence to disease modifying therapy in patients with multiple sclerosis. J Neurosci Nurs. 2018;50(5):291–297. doi:10.1097/JNN.0000000000000395
   PubMedGoogle Scholar
• Maroney M, Hunter SF. Implications for multiple sclerosis in the era of the Affordable Care Act: a clinical overview. Am J Manag Care. 2014;20(11 Suppl):S220–227.
   Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease modifying therapies among patients with multiple sclerosis. J Manage Care Pharm. 2013;19(1 Supp A):S24–S40. doi:10.18553/jmcp.2013.19.s1.S24
   Web of Science ®Google Scholar
• Palmer L, Abouzaid S, Shi N, et al. Impact of patient cost sharing on multiple sclerosis treatment. Am J Pharm Benefits. 2012;4(Special Issue):SP28–SP36.
   Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9. doi:10.2147/PPA.S8230
   PubMed Web of Science ®Google Scholar
• Higuera L, Carlin CS, Anderson S. Adherence to disease modifying therapies for multiple sclerosis. J Manage Care Spec Pharm. 2016;22(12):1394–1401. doi:10.18553/jmcp.2016.22.12.1394
   PubMed Web of Science ®Google Scholar
• Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl 6):87–92. doi:10.1007/s00415-008-6016-8
   PubMed Web of Science ®Google Scholar
• Hao J, Pitcavage J, Jones JB, Hoegerl C, Graham J. Measuring adherence and outcomes in the treatment of patients with multiple sclerosis. J Am Osteopath Assoc. 2017;117(12):737–747.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease modifying therapies for multiple sclerosis in clinical practice. Mult Scler J Exp Transl Clin. 2016;2.
   Google Scholar
• Desai RJ, Mahesri M, Gagne JJ, et al. Utilization patterns of oral disease modifying drugs in commercially insured patients with multiple sclerosis. J Manag Care Spec Pharm. 2019;25(1):113–121.
   Web of Science ®Google Scholar
• Burks J. Adherence to disease modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. - PubMed - NCBI. 2018.
   Google Scholar
• Munsell M, Frean M, Menzin J, Phillips AL. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease modifying drug. Patient Prefer Adherence. 2017;11:55–62. doi:10.2147/PPA.S118107
   PubMed Web of Science ®Google Scholar
• Dionne C, G R, C A, C C. Abstract: Do Oral Disease Modifying Agents (DMTs) Improve Adherence to MS Treatment? A Comparison of Oral and Injectable Drugs (2015 CMSC Annual Meeting). https://cmsc.confex.com/cmsc/2015/webprogram/Paper3275.html. 2015.
   Google Scholar
• Sabido-Espin M, Munschauer R. Reasons for discontinuation of subcutaneous interferon beta-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC Neurol. 2017;17(1):57.
   Google Scholar
• Lanzillo R, Prosperini L, Gasperini C, et al. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol. 2018;265(5):1174–1183. doi:10.1007/s00415-018-8831-x
   PubMed Web of Science ®Google Scholar
• Ferraro D, Camera V, Baldi E, et al. First-line disease modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Curr Med Res Opin. 2018;34(10):1803–1807. doi:10.1080/03007995.2018.1451311
   PubMed Web of Science ®Google Scholar
• Burks J, Marshall TS, Ye X. Adherence to disease modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251–260.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17(10):696–707. doi:10.3111/13696998.2014.940422
   PubMedGoogle Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:9.
   Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013;29(12):1647–1656. doi:10.1185/03007995.2013.847411
   PubMed Web of Science ®Google Scholar
• Nazareth T, Friedman HS, Navaratnam P, et al. Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease modifying therapies: a retrospective medical record review. BMC Neurol. 2016;16(1):187.
   Google Scholar
• Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24(10):1105–1113. doi:10.1002/pds.3787
   PubMed Web of Science ®Google Scholar
• Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789–796.
   PubMed Web of Science ®Google Scholar
• Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65(2–3):205–210. doi:10.1159/000360229
   PubMed Web of Science ®Google Scholar
• Nicholas J, Edwards NC, Edwards RA, et al. ND3 Use of group-based trajectory modeling to identify adherence clusters in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease modifying agents. Value Health. 2019;22:S43. doi:10.1016/j.jval.2019.04.061
   Web of Science ®Google Scholar
• Hansen L. The Truven Health MarketScan^® Databases for Life Sciences Researchers. Ann Arbor: Truven Health Analytics; 2017.
   Google Scholar
• Andersen R. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10. doi:10.2307/2137284
   PubMed Web of Science ®Google Scholar
• Truven Health MarketScan^®Database.
   Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: past, present and future. Clin Invest Med. 2019;42(1):E5–e12. doi:10.25011/cim.v42i1.32383
   Google Scholar
• Marrie RA, Miller A, Sormani MP, et al. Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology. 2016;86(15):1446–1453. doi:10.1212/WNL.0000000000002474
   Web of Science ®Google Scholar
• HCUP-US Tools & Software Page. 2020. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
   Google Scholar
• Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27. doi:10.1097/00005650-199801000-00004
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101–111. doi:10.1016/j.msard.2018.09.038
   PubMed Web of Science ®Google Scholar
• Pyenson B, Tomicki S. Multiple Sclerosis: New Perspectives on the Patient Journey: 2019 Update. NY: Milliman Inc.; 2019.
   Google Scholar
• Nicholas J, Boster A, Wu N, et al. Comparison of disease modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data. PharmacoEconomics Open. 2018;2(1):31–41. doi:10.1007/s41669-017-0035-2
   Web of Science ®Google Scholar
• Vadhariya A, Fleming ML, Johnson ML, et al. Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults. Am Health Drug Benefits. 2019;12(4):202–211.
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–1288. doi:10.1345/aph.1H018
   PubMed Web of Science ®Google Scholar
• Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44. doi:10.1345/aph.1K671
   PubMed Web of Science ®Google Scholar
• Pednekar PP, Agh T, Malmenäs M, et al. Methods for measuring multiple medication adherence: a systematic review–report of the ISPOR medication adherence and persistence special interest group. Value Health. 2019;22(2):139–156. doi:10.1016/j.jval.2018.08.006
   PubMed Web of Science ®Google Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138. doi:10.1186/1471-2377-13-138
   PubMed Web of Science ®Google Scholar
• Alhazami M, Pontinha VM, Patterson JA, Holdford DA. Medication adherence trajectories: a systematic literature review. J Manage Care Spec Pharm. 2020;26(9):1138–1152. doi:10.18553/jmcp.2020.26.9.1138
   Web of Science ®Google Scholar
• Nagin DS. Group-based trajectory modeling: an overview. In: Handbook of Quantitative Criminology. Springer; 2010:53–67.
   Google Scholar
• Nagin D, Tremblay R. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol Methods. 2001;6(1):18–34. doi:10.1037/1082-989X.6.1.18
   PubMed Web of Science ®Google Scholar
• Arrandale V, Koehoorn M, MacNab Y, Kennedy MS How to use SAS^® Proc Traj and SAS^® Proc Glimmix in Respiratory Epidemiology. 2006.
   Google Scholar
• Wabe N, Wojciechowski J, Wechalekar MD, et al. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. Int J Rheum Dis. 2017;20(10):1447–1456. doi:10.1111/1756-185X.13184
   Web of Science ®Google Scholar
• Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–611.
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Schulte PJ, Mascha EJ. Propensity score methods: theory and practice for anesthesia research. Anesth Analg. 2018;127(4):1074–1084. doi:10.1213/ANE.0000000000002920
   PubMed Web of Science ®Google Scholar
• Nicholas J, Ontaneda D, Carraro M, et al. Development of an algorithm to identify Multiple Sclerosis (MS) disease severity based on healthcare costs in a US Administrative Claims Database (P2. 052). AAN Enterprises. 2017.
   Google Scholar